Canan Alhan

Canan Alhan

UNVERIFIED PROFILE

Are you Canan Alhan?   Register this Author

Register author
Canan Alhan

Canan Alhan

Publications by authors named "Canan Alhan"

Are you Canan Alhan?   Register this Author

19Publications

833Reads

50Profile Views

Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations.

Cytometry B Clin Cytom 2016 07 14;90(4):358-67. Epub 2015 Dec 14.

Department of Hematology, Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21333DOI Listing
July 2016

Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias.

Eur J Cancer 2016 Feb 22;54:49-56. Epub 2015 Dec 22.

Department of Hematology, VU University Medical Center, Cancer Center Amsterdam (VUmc CCA), De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.11.013DOI Listing
February 2016

Immunophenotyping for diagnosis and prognosis in MDS: ready for general application?

Best Pract Res Clin Haematol 2015 Mar 11;28(1):14-21. Epub 2014 Nov 11.

Department of Hematology, VU University Medical Center, Cancer Center Amsterdam (VUmc CCA), Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2014.11.003DOI Listing
March 2015

High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes.

Br J Haematol 2014 Oct 30;167(1):100-9. Epub 2014 Jun 30.

Department of Haematology, Cancer Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12994DOI Listing
October 2014

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Cytometry B Clin Cytom 2014 May 28;86(3):207-15. Epub 2014 Jan 28.

Department of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21160DOI Listing
May 2014

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Cytometry B Clin Cytom 2014 Jan 15. Epub 2014 Jan 15.

Department of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cytob.21160DOI Listing
January 2014

Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes.

Leuk Res 2012 Jul 14;36(7):921-30. Epub 2012 Apr 14.

Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081HV Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.03.026DOI Listing
July 2012

Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.

Br J Haematol 2011 Jun 13;153(5):568-81. Epub 2011 Apr 13.

Department of Haematology, VU Institute for Cancer and Immunology, VU University Medical Centre, Amsterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2011.08683.xDOI Listing
June 2011